RU93005355A - Фармакологические композиции - Google Patents

Фармакологические композиции

Info

Publication number
RU93005355A
RU93005355A RU93005355/14A RU93005355A RU93005355A RU 93005355 A RU93005355 A RU 93005355A RU 93005355/14 A RU93005355/14 A RU 93005355/14A RU 93005355 A RU93005355 A RU 93005355A RU 93005355 A RU93005355 A RU 93005355A
Authority
RU
Russia
Prior art keywords
pharmacological compositions
lesions
excretions
psoriasis
malignant
Prior art date
Application number
RU93005355/14A
Other languages
English (en)
Other versions
RU2119333C1 (ru
Inventor
Боллаг Вернер
Франсис Гриппо Джозеф
Левин Артур
Original Assignee
Хоффманн Ля Рош АГ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хоффманн Ля Рош АГ filed Critical Хоффманн Ля Рош АГ
Publication of RU93005355A publication Critical patent/RU93005355A/ru
Application granted granted Critical
Publication of RU2119333C1 publication Critical patent/RU2119333C1/ru

Links

Claims (1)

  1. Фармакологические композиции, в том числе 9-цис ретиноевая кислота, ее соли и сложные эфиры могут использоваться при лечении злокачественных и предзлокачественных поражений эпителия, лучевых повреждений кожи, заболеваний, вызванных усиленным салоотделением, и псориаза.
RU93005355A 1992-01-22 1993-01-20 Фармацевтический состав RU2119333C1 (ru)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US82374192A 1992-01-22 1992-01-22
US82392892A 1992-01-22 1992-01-22
US82378692A 1992-01-22 1992-01-22
US823786 1992-01-22
US823741 1992-01-22
US82464792A 1992-01-23 1992-01-23
US824647 1992-01-23
US823928 1997-03-25

Publications (2)

Publication Number Publication Date
RU93005355A true RU93005355A (ru) 1995-09-27
RU2119333C1 RU2119333C1 (ru) 1998-09-27

Family

ID=27505866

Family Applications (1)

Application Number Title Priority Date Filing Date
RU93005355A RU2119333C1 (ru) 1992-01-22 1993-01-20 Фармацевтический состав

Country Status (20)

Country Link
EP (1) EP0552624B1 (ru)
JP (1) JP3631259B2 (ru)
CN (2) CN1068200C (ru)
AT (1) ATE194077T1 (ru)
AU (1) AU667864B2 (ru)
CA (1) CA2087251C (ru)
CY (1) CY2251B1 (ru)
CZ (1) CZ282548B6 (ru)
DE (1) DE69328910T2 (ru)
DK (1) DK0552624T3 (ru)
ES (1) ES2148184T3 (ru)
GR (1) GR3034323T3 (ru)
HU (2) HU212734B (ru)
IL (1) IL104450A (ru)
NO (1) NO302274B1 (ru)
NZ (1) NZ245686A (ru)
PH (1) PH31621A (ru)
PT (1) PT552624E (ru)
RU (1) RU2119333C1 (ru)
TW (1) TW226329B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2214830C2 (ru) * 2001-12-03 2003-10-27 Рязанский государственный медицинский университет им. акад. И.П.Павлова Способ лечения и профилактики местных лучевых реакций на коже

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE617614T1 (de) 1991-12-18 1995-06-08 Baylor College Of Medicine, Houston, Tex. Mitteln zur modulierung von verfahren durch retinoid rezeptoren und dafür nützliche verbindungen.
US5968989A (en) 1991-12-18 1999-10-19 The Salk Institute For Biological Studies Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
US7056954B2 (en) 1991-12-18 2006-06-06 The Salk Institute For Biological Studies Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
US5780676A (en) * 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
US5962731A (en) * 1992-04-22 1999-10-05 Ligand Pharmaceuticals Incorporated Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
US7655699B1 (en) 1992-04-22 2010-02-02 Eisai Inc. Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
US5549888A (en) * 1994-01-31 1996-08-27 Procter & Gamble Aqueous topical anti-acne compositions of low pH
US5534261A (en) * 1995-01-17 1996-07-09 University Of Southern California Retinoid-based compositions and method for preventing adhesion formation using the same
US7115728B1 (en) 1995-01-30 2006-10-03 Ligand Pharmaceutical Incorporated Human peroxisome proliferator activated receptor γ
US5821254A (en) * 1995-02-17 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer
US5807900A (en) * 1995-03-31 1998-09-15 Hoffmann-La Roche, Inc. Method for identifying compounds having increased activity for the repair of skin photodamage
AU5721096A (en) * 1995-04-21 1996-11-07 Ligand Pharmaceuticals Incorporated Inhibition of apoptosis in cells expressing fas-ligand follo wing activation
DE19523079A1 (de) * 1995-06-26 1997-01-02 Basf Ag Ester und Amide der 9(Z)-Retinsäure
EP0788353A1 (en) 1995-09-18 1997-08-13 Ligand Pharmaceuticals, Inc. Ppar gamma antagonists for treating obesity
PT859608E (pt) * 1995-09-18 2004-06-30 Ligand Pharm Inc Tratamento de niddm com agonistas de rxr
TW442459B (en) * 1996-04-15 2001-06-23 Hoffmann La Roche Retinoid compounds, pharmaceutical composition comprising same and process for the preparation thereof
FR2765480B1 (fr) 1997-07-07 1999-09-10 Oreal Utilisation pour le revetement des matieres keratiniques d'un materiau polymerique hybride ; compositions cosmetiques ou dermatologiques
WO1999005161A1 (en) 1997-07-25 1999-02-04 Ligand Pharmaceuticals Incorporated HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARη) GENE REGULATORY SEQUENCES AND USES THEREFOR
AU1707599A (en) * 1998-03-20 1999-10-18 Warner-Lambert Company Retinoid-glitazone combinations
HUP0200996A3 (en) 1999-04-07 2003-01-28 Sankyo Company Ltd Chuo Ku Amine derivatives, pharmaceutical compositions containing them and their use
CA2392453C (en) * 1999-11-23 2012-03-20 Gerhart Graupner Modulation of signal transduction
JP5249484B2 (ja) * 2001-12-11 2013-07-31 第一三共株式会社 医薬組成物
RU2197235C1 (ru) * 2002-04-05 2003-01-27 Фармацевтическое научно-производственное предприятие "Ретиноиды" (акционерное общество закрытого типа) Раствор для лечения заболеваний кожи, способ его получения и способ лечения заболеваний кожи
US20050245440A1 (en) * 2002-04-05 2005-11-03 University Of Utah Research Foundation Regulation of a novel colon specific retinol dehydrogenase by apc and cdx2
US20040122110A1 (en) * 2002-09-06 2004-06-24 Maccabee Mendy S. Effect of vitamin A gel on paranasal sinus mucosal regeneration
EP1527774A1 (en) 2003-11-03 2005-05-04 Basilea Pharmaceutica AG New formulation for retinoid-containing soft gelatin capsules
JP4825957B2 (ja) * 2005-03-29 2011-11-30 国立大学法人 鹿児島大学 抗腫瘍剤
RU2546005C2 (ru) 2009-09-15 2015-04-10 Кью Эл Ти ИНК. Фармацевтические составы, содержащие 9-цис-ретиниловые сложные эфиры в липидном наполнителе
JP2013527155A (ja) * 2010-04-16 2013-06-27 ダボス ライフ サイエンス ピーティーイー． リミテッド 皮膚科用途のための少なくとも１つのビタミンｅ成分およびチロシナーゼ阻害剤の相乗的相互作用
SG10201507819VA (en) 2010-04-19 2015-10-29 Quadra Logic Tech Inc Therapeutic Regimen And Methods For Treating Or Ameliorating Visual Disorders Associated With An Endogenous Retinoid Deficiency
AU2013232697B2 (en) 2012-03-01 2017-10-19 Eluminex Biosciences (Suzhou) Limited Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
JP6182728B2 (ja) * 2012-11-02 2017-08-23 国立大学法人名古屋大学 幹細胞を標的とした薬効及び毒性の評価法
US20230320967A1 (en) 2020-09-11 2023-10-12 Chemyunion Ltda. Composition, use of the composition, cosmetic method for modulating the production of sebum
EP4489744A4 (en) * 2022-03-08 2025-11-05 Mastery Biotech Co Ltd PHARMACEUTICAL COMPOSITION COMPRISING RETINOIC ACID AND A CARBOHYDRATE AND ITS USE
WO2025077810A1 (zh) * 2023-10-12 2025-04-17 南京纽邦生物科技有限公司 预防或延缓皮肤衰老及维持或改善皮肤状况的方法和组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA713539B (en) * 1970-06-23 1972-02-23 Hoffmann La Roche Pharmaceutical compositions
WO1988007857A1 (en) * 1987-04-06 1988-10-20 Daltex Medical Sciences, Inc. Treatment of aged skin with oral 13-cis-retinoic acid
US4994491A (en) * 1988-12-14 1991-02-19 Molecular Design International Dermal uses of trans-retinoids for the treatment of cancer
LU86969A1 (fr) * 1987-08-12 1989-03-08 Oreal Association de derives de pyrimidine et de retinoides en composants separes pour induire et stimuler la croissance des cheveux et diminuer leur chute
DE617614T1 (de) * 1991-12-18 1995-06-08 Baylor College Of Medicine, Houston, Tex. Mitteln zur modulierung von verfahren durch retinoid rezeptoren und dafür nützliche verbindungen.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2214830C2 (ru) * 2001-12-03 2003-10-27 Рязанский государственный медицинский университет им. акад. И.П.Павлова Способ лечения и профилактики местных лучевых реакций на коже

Similar Documents

Publication Publication Date Title
CA2087251A1 (en) Pharmaceutical compositions
RU2008118056A (ru) Применение 6-[3-(1-адамантил)-4-метоксифенил]-2-нафтойной кислоты для лечения дерматологических расстройств
PT772600E (pt) Compostos de imidazolilo substituido nas posicoes 1 e 2 para o tratamento da inflamacao
ES2151607T3 (es) Factor 12 de crecimiento y de diferenciacion.
DE69315927D1 (de) Kosmetische Zusammensetzung, die einen Lipidstoff und eine Hydroxy - oder Ketofettsäure enthält
SE7410757L (ru)
DE69716947D1 (de) Orale zusammenstellung die 5-aminosalicylsäure enthält
KR930016100A (ko) 약제학적 조성물
ES8102141A1 (es) Un procedimiento para preparar compuestos de acido 3-cefem-4-carboxilico disustituido en las posiciones 3 y 7
ATE113209T1 (de) Verwendung von 5-amino-salicylsäure für die behandlung von hautkrankheiten.
DK0700897T3 (da) L-carnitinsalt og kosmetiske og farmaceutiske præparater indeholdende samme til behandling af hudsygdomme
SE8102161L (sv) "3,7,11,15-tetrametyl-2,4,6,10,14-hexadekapentaensyra
ES2064958T3 (es) Gel acuoso a base de acido retinoico y de hidroxipropil-beta-ciclodextrina.
EP0357646A4 (en) Treatment of aged skin with oral 13-cis-retinoic acid
DE69018570D1 (de) Wasserlösliche Vitamin A-Zubereitungen und deren Verwendung bei der Hautbehandlung.
Cormie Perifolliculitis capitis abscedens et suffodiens
RU94016406A (ru) Способ лечения рожистого воспаления
IT1075668B (it) Complessi di alcoli con fosfato d'estramustina,loro preparazione,e loro impiego come intermedi nella purificazione di detto composto e di suoi sali
RU97107046A (ru) Мазь "аникол" для лечения ран, воспалительных и кожных заболеваний у животных
IT1211103B (it) Sostanza medicamentosa ad impiego topico per il trattamento delle affezioni provocate dalla seborrea sul cuoio capelluto umano.
IT1099795B (it) Composizione terapeutica per il trattamento di infezioni e malattie di animali da allevamento
RU95100066A (ru) Способ наружного лечения микозов стоп и гладкой кожи
ATE92462T1 (de) Entzuendungshemmendes mittel zur behandlung der krankhaften prostataerweiterung, ein verfahren fuer seine herstellung und dieses enthaltende pharmazeutische zusammensetzungen.
IT8024347A0 (it) L'applicazione di 4-arilchinazolin-2(1h)-oni per il trattamento delle malattie autoimmuni dei tessuti connettivi.
IT8448370A0 (it) Citrato trisodico utilizzabile nella cura delle malattie artriticoreumatiche